clinical trial · NCT07284654
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
Pneumococcal Vaccines31 valent pneumococcal conjugate vaccinePCV20PCV21
brief summary
The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults ≥50 years of age, and to bridge the immune responses induced by VAX-31 in adults 50-64 years of age to adults 18-49 years of age.
started
Dec 1, 2025
primary completion
Jan 1, 2027
completion
Jan 1, 2027
last updated
May 15, 2026
official title
A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Immunobridging to Subjects 18-49 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol